2 great ASX shares to buy in April: experts

Temple & Webster is one ASX share rated as an opportunity.

| More on:
ASX shares upgrade buy Woman in glasses writing on buy on board

Image Source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • These 2 ASX shares are delivering rapid revenue growth
  • Temple & Webster is one of the biggest online-only retailers in Australia
  • Volpara is a breast screening business, with a market share of 35% in the US

Experts have named some ASX shares as buys, and April 2022 could be the time to jump on these opportunities.

When a business generates a lot of revenue growth, it could lead to elevated compound growth over time.

Here are two ASX shares that are liked:

Temple & Webster Group Ltd (ASX: TPW)

Temple & Webster is an e-commerce business that sells an extensive range of different homewares and furniture products. It sells more than 200,000 products from hundreds of suppliers.

The business runs a drop-shipping model where products are sent directly to customers by suppliers, which enables faster delivery times and reduces the need to hold inventory, allowing for a more extensive product range.

The ASX share also has a private label range, which is sourced from overseas suppliers.

Temple & Webster is generating growth in numerous ways. In the FY22 first half, revenue increased 46% year-on-year to $235.4 million. Active customers grew 34% to 906,000, and revenue per active customer rose 10%.

According to management, the second half of FY22 started "strongly", with year-on-year growth of 26% for the period of 1 January 2022 to 6 February 2022.

Management said it remains confident that the strategy is resonating with the next generation of shopper and it's well placed to continue to take share in the markets it's operating in.

It is continuing to reinvest its operating leverage where it makes sense to do so, building strategic moats around the core business while investing in new growth horizons.

It's currently rated as a buy by Credit Suisse, with a price target of $13.54. The Temple & Webster share price closed on Thursday at $6.26, suggesting a potential upside of 116%.

Volpara Health Technologies Ltd (ASX: VHT)

Volpara Health Technologies is an ASX healthcare share that offers software for screening clinics providing feedback on breast density, compression, dose, and quality, while its enterprise-wide practice-management software helps with productivity, compliance, reimbursement, and patient tracking.

The business is seeing steady growth in its annual recurring revenue (ARR), which gives the company and investors revenue visibility.

For the three months to 31 December 2021, Volpara added almost US$1.1 million of ARR. The ARR reached US$21.5 million. In that quarter, subscription receipts rose 51% to NZ$6.7 million.

Its market share has now reached more than 35% of US women being screened, up from the prior quarter of 34%. Its software-as-a-service (SaaS) churn/client loss remains low.

The company is looking to upsell more of its products to clients, which could help the average revenue per user (ARPU). ARPU over the installed base was US$1.47 on 31 December 2021, with the average ARPU for deals in the third quarter of US$1.65.

The ASX share is also looking to grow in the lung cancer space. It entered the lung cancer screening world in 2019 when it acquired MRS Systems, with a market share of 8%.

Volpara says that software technology 'stacks' are similar, "except diagnostic tools are more compelling in the lung space due to the complexity of doing lung biopsies as compared to breast".

Volpara believes the commercial opportunities in lung cancer screening are at least equal to breast screening as lung screening ramps up. It estimates the market could be $400 million in the US alone.

It's currently rated as a buy by Morgans, with a price target of $1.94. That's 54% higher than Thursday's closing price of 89 cents.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Temple & Webster Group Ltd and VOLPARA FPO NZ. The Motley Fool Australia owns and has recommended VOLPARA FPO NZ. The Motley Fool Australia has recommended Temple & Webster Group Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Growth Shares

A smiling man take a big bite out of a burrito
Growth Shares

Looking for ASX growth shares? I rate these 2 as buys

I’m backing these investments to deliver big returns.

Read more »

A bland looking man in a brown suit opens his jacket to reveal a red and gold superhero dollar symbol on his chest.
Growth Shares

Macquarie says these ASX 200 growth shares can rise 20% to 35%

Let's see what the broker is saying about these growing companies.

Read more »

Growth Shares

Why Zip shares and this ASX 200 stock are a buy according to this fund manager

These stocks could be leading contenders to deliver returns in the ASX 200.

Read more »

A man working in the stock exchange.
Growth Shares

Buy these 2 impressive ASX 300 shares in July: experts

Experts are bullish on these stocks.

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Growth Shares

1 of the best ASX growth stocks to consider buying in July

I’m calling this stock one of the leading growth opportunities.

Read more »

a group of tech people gather around a computer operated by a young woman while the group looks on in support.
Growth Shares

3 of the best Australian stocks to buy and hold forever

These high-quality shares are rated as buys by brokers for a reason.

Read more »

$100 Australian notes on top of each other.
Growth Shares

Where to invest $10,000 into ASX shares in July

Analysts are raving about these shares. But why are they buys?

Read more »

Four piles of coins, each getting higher, with trees on them.
Growth Shares

2 ASX growth shares to buy this month: experts

These stocks are expected to have a strong next few years…

Read more »